<DOC>
	<DOCNO>NCT01641640</DOCNO>
	<brief_summary>This study ass whether sofosbuvir combination ribavirin ( RBV ) pegylated interferon alfa 2a ( PEG ) administer 12 week safe effective patient hepatitis C virus ( HCV ) genotypes 1 , 4 , 5 , 6 assessed rate sustain viral response ( SVR ) 12 week discontinuation therapy ( SVR12 ) .</brief_summary>
	<brief_title>Sofosbuvir With Peginterferon Alfa 2a Ribavirin 12 Weeks Treatment-Naive Subjects With Chronic Genotype 1 , 4 , 5 , 6 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Infection HCV genotype 1 , 4 , 5 , 6 Cirrhosis determination Subject meet follow classification : Treatmentnaive Screening laboratory value within define threshold Not treat investigational drug device within 30 day screen Use highly effective contraception method female childbearing potential sexually active male Prior exposure directacting antiviral target HCV nonstructural protein ( NS ) 5B polymerase Pregnant nursing female , male pregnant female partner Current prior history clinical hepatic decompensation History clinicallysignificant illness major medical disorder may interfere subject treatment , assessment , compliance protocol Excessive alcohol ingestion significant drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>HCV genotype 1 ( GT-1 )</keyword>
	<keyword>HCV genotype 4 ( GT-4 )</keyword>
	<keyword>HCV genotype 5 ( GT-5 )</keyword>
	<keyword>HCV genotype 6 ( GT-6 )</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>Treatment-Na√Øve</keyword>
	<keyword>GS-7977</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>RBV</keyword>
	<keyword>Peginterferon Alfa 2a</keyword>
	<keyword>PEG</keyword>
</DOC>